Hand eczema and quality of life: a population-based study

Moberg, Cecilia; Alderling, Magnus; Meding, Birgitta

doi:10.1111/j.1365-2133.2009.09099.x

Cited by 149 publications

(156 citation statements)

References 29 publications

(33 reference statements)

Supporting

Mentioning

138

Contrasting

Unclassified

Order By: Relevance

“…Ten studies, reported in 13 publications, used the EuroQol instrument, and reported either the European Quality of Life-5 Dimensions (EQ-5D) utility score [62][63][64][65][66][67] or the visual analogue scale (VAS) score. [68][69][70][71][72][73] One study reported utilities obtained by the HUI Mark III instrument.…”

Section: Resultsmentioning

confidence: 99%

“…74 Three studies used a direct utility elicitation technique. [75][76][77] The 10 studies reported on 28 populations: 14 studies with rhinitis/rhinosinusitis/ rhinoconjunctivitis/asthma, [62][63][64][65][66][68][69][70][71][72][73]78 11 studies with eczema, 67,73,[75][76][77] two studies with food allergy 73,74 and one study with mixed allergies except food allergies. 74 Utility values ranged from 0.5000 for patients with allergic rhinitis receiving allergy vaccination 72 to 0.970 for persons with mild eczema.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis

Westwood

Ramaekers

Lang

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

BackgroundAllergy is a form of immune-mediated exaggerated sensitivity (hypersensitivity) to a substance that is either inhaled, swallowed, injected or comes into contact with the skin. Foreign substances that provoke allergies are called allergens. It has been claimed that multiplex allergen testing may help in diagnosing the cause of symptoms in patients with an unclear cause of allergy or who are allergic to more than one substance.ObjectivesTo evaluate multiplex allergen testing [devices that can measure the presence of multiple immunoglobulin E (IgE) antibodies in a patient’s blood at the same time], by assessing (1) clinical effectiveness (allergy symptoms, incidence of acute exacerbations, mortality, adverse events of testing and treatment, health-care presentations or admissions, health-related quality of life); (2) effects on treatment (diet, immunotherapy medications, other potential testing); (3) any additional diagnostic information provided by multiplex allergen testing; and (4) cost-effectiveness (cost of different assessment strategies).MethodsFifteen databases were searched from 2005 to April 2015, including MEDLINE (via OvidSp), MEDLINE In-Process Citations, MEDLINE Daily Update, PubMed (National Library of Medicine), EMBASE, Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA) database, Science Citation Index (SCI), Conference Proceedings Citation Index-Science (CPCI-S), BIOSIS Previews, Latin American and Caribbean Health Sciences Literature (LILACS), National Institute for Health Research (NIHR) HTA programme, and the US Food and Drug Administration (FDA); supplementary searches of conference proceedings and trials registries were performed. Review methods followed published guidance from the Cochrane Collaboration and the Centre for Reviews and Dissemination, University of York, UK. The methodological quality of included studies was assessed using appropriate published tools or a review-specific tool designed by the project team. Studies were summarised in a narrative synthesis. Owing to a lack of data on the clinical effectiveness of multiplex allergen testing, no long-term cost-effectiveness model was developed. A conceptual model structure was developed and cost analyses were performed to examine the short-term costs of various possible diagnostic pathways.ResultsFifteen studies were included in the review. The very limited available data indicated that the addition of multiplex allergen testing [ImmunoCAP®Immuno Solid-phase Allergen Chip (ISAC), Thermo Fisher Scientific/Phadia AB, Uppsala, Sweden] to standard diagnostic work-up can change the clinicians’ views on the diagnosis, management and treatment of patients. There was some indication that the use of ImmunoCAP ISAC testing may be useful to guide decisions on the discontinuation of restrictive diets, the content of allergen-specific immunotherapy (SIT) prescriptions, and whether or not patients should receive SIT. However, none of the studies that we identified reported any information on clinical outcomes subsequent to changes in treatment or management. There was some evidence that ImmunoCAP ISAC may be useful for discriminating allergens that are structurally similar and are recognised by the same IgE antibody (cross-immunoreactive). No data were available for Microtest (Microtest Matrices Ltd, London, UK). Detailed cost analyses suggested that multiplex allergen testing would have to result in a substantial reduction of the proportions of patients receiving single IgE testing and oral food challenge tests in order to be cost-saving in the short term.ConclusionsNo recommendations for service provision can be made based on the analyses included in this report. It is suggested that a consensus-based protocol for the use of multiplex allergen testing be developed. The clinical effectiveness and cost-effectiveness of the proposed protocol should then be assessed by comparing long-term clinical and quality of life outcomes and resource use in patients managed using the protocol with those managed using a standard diagnostic pathway.Study registrationThis study is registered as PROSPERO CRD42015019739.FundingThis project was a Diagnostic Assessment Report commissioned by the NIHR HTA programme on behalf of the National Institute for Health and Care Excellence.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis

Westwood

Ramaekers

Lang

et al. 2016

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…As severe chronic hand eczema (HE) causes considerable occupational, social and psychological disability [1,2,3], comprehensive primary prevention strategies at the workplace are needed. The economic and social impact of occupational HE is considerable for both the individual and society.…”

Section: Introductionmentioning

confidence: 99%

Does Smoking Have a Significant Impact on Early Irritant Hand Dermatitis in Metal Workers?

Kütting

Uter²,

Weistenhöfer³

et al. 2011

Dermatology

View full text Add to dashboard Cite

Background: Although they know the long-term complications of smoking, many smokers require additional motivation for entering a smoking cessation programme. At the same time, smoking is considered a possible promoting factor for various skin diseases. Objective: The present study assesses the impact of smoking on occupational hand dermatitis in a high-risk population. Material and Methods: 1,355 metal workers, 97.3% of them shift workers, took part in a standardized interview and a dermatological examination of their hands. A subgroup of 1,020 males was willing to be followed-up for 1 year. Of those, 78.3% could be included in the final assessment. Results: Compared to the general German adult population the percentage of smokers was increased (41.7% at baseline). Probably due to self-selection bias and to a higher drop-out rate, the proportion of smokers was significantly lower at follow-up. Compared to nonsmokers, smokers had significantly higher score values for both erythematous lesions and vesicles. Conclusion: The present data might give additional support for occupational physicians or dermatologists to convince workers to quit smoking.

show abstract

“…HE may be disabling and has widespread personal consequences, such as job loss and impaired quality of life (24,25). It is a multifactorial disease, and it is important for patients with HE to know how lifestyle factors may impact on their disease.…”

mentioning

confidence: 99%

Tobacco smoking and hand eczema – is there an association?

et al. 2015

View full text Add to dashboard Cite

SummaryBackground. Numerous risk factors have been suggested for hand eczema. This systematic review evaluates the association between tobacco smoking and hand eczema. Objective. To review the literature systematically on the association between smoking and hand eczema. Methods. The PubMed and EMBASE databases were searched up to 27 January 2015 for articles on the association between tobacco smoking and hand eczema, including human studies in English and German only. Experimental studies, studies on tobacco allergy, case reports, reviews and studies on second-hand smoking were excluded. Results. Twenty articles were included. Among studies in occupational settings, three of seven found a statistically significant positive association between tobacco smoking and hand eczema prevalence rate, as did four of eight population-based studies. The association was stronger for studies in occupational settings than for population-based studies. No studies reported tobacco to be a clear protective factor for hand eczema. Two of five studies regarding severity found a positive association between smoking and hand eczema severity. Conclusion. Overall, the data indicate that smoking may cause an increased frequency of hand eczema, particularly in high-risk occupations. However, data from studies controlling for other risk factors are conflicting, and few prospective studies are available. Studies controlling for other risk factors are needed, and information regarding the diagnosis of subclasses of hand eczema, as well as severity, may be important.

show abstract

Hand eczema and quality of life: a population-based study

Cited by 149 publications

References 29 publications

ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis

ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis

Does Smoking Have a Significant Impact on Early Irritant Hand Dermatitis in Metal Workers?

Tobacco smoking and hand eczema – is there an association?

Contact Info

Product

Resources

About